Menu Login / Registration Search
CZ

CLIA IA-2

The chemiluminescence assay is intended for use as an aid in the diagnosis of diabetes mellitus type I. using IgG antibodies to GAD65 in human serum or plasma in the general population. The quantitative automated assay is designed for professional use in a laboratory.

New
Catalog Number: CL-IA100
Size: 100 tests
Regulatory status: CE IVD
Clinical topic: Diabetes & Metabolism Disorders
Diagnostic panel: Diabetes
Producer: TestLine Clinical Diagnostics s.r.o.
CLIA IA-2

IA-2 is an autoantibody marker associated with autoimmune damage to the pancreatic beta cells. It is frequently present in patients with newly diagnosed type 1 diabetes and typically reflects a more active autoimmune process with faster disease progression.

Testing for IA-2 naturally complements GAD65 and increases the overall sensitivity of autoimmune diabetes diagnostics, particularly in patients with unclear classification. While GAD65 is typically found in adult patients with a slower disease course, such as LADA, IA-2 more commonly appears in cases where diabetes progresses more rapidly.

The combination of both markers therefore provides a more comprehensive diagnostic picture and enables the identification of patients with autoimmune diabetes before the disease has fully developed.

The portfolio of markers for functional pancreatic assessment, C-peptide and Insulin, complemented by autoimmune diabetes markers GAD65 and IA-2, which are not commonly available on other CLIA platforms, represents a significant advantage of the CLIA solution from BioVendor Group.

Benefits of BioVendor Group's Diabetes Panel on the CLIA Platform

  • The combination of functional and autoimmune markers enables more precise differentiation of type 1 diabetes, LADA, and type 2 diabetes
  • Supports early diagnosis of autoimmune diabetes, including in patients with an atypical disease course or unclear classification
  • Increases clinical value in situations where standard classification is insufficient and contributes to a better understanding of disease etiology
  • Streamlines the testing process and simplifies the interpretation of results
  • GAD65 and IA-2 markers in CLIA format on a fully automated platform ensure a high level of automation and maximum user convenience

Benefits of Automated CLIA Tests for GAD65 and IA-2
The CLIA method offers a number of practical advantages over the established ELISA and RIA methods for routine laboratory operations:

  • Automated CLIA tests for GAD65 and IA-2 significantly reduce hands-on time
  • Tests provide shorter analysis time and faster availability of results for clinical decision-making
  • CLIA method ensures a higher level of standardization, better reproducibility, and improved consistency of results
  • Unlike the RIA method, it requires no radioactive materials, ensuring safer operation

Technical specifications

Technical data
References
Related Products
Downloads

Technical data

Assay time30 min
Assay stability30 days on board stability / In use stability until the expiration date at storage temperature 2-8 °C
Sample matrix Serum, Plasma
Sample volume30 µL
Measuring range0–500 U/ml
Assay/kit contentReagent Cartridge with specific reagents for the assay, magnetic beads, calibrators
Complementary productsAnchorĀ® Tips, Stackable Cuvette, KleeYa Trigger Pack, KleeYa Wash buffer
Note

The kits are CE-IVD certified and intended for professional use.

References

  • Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Lernmark Å, Metzger BE, Nathan DM, Kirkman MS. Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. Diabetes Care. 2023 Oct 1;46(10):e151-e199. doi: 10.2337/dci23-0036. PMID: 37471273; PMCID: PMC10516260.
    See more on PubMed
  • Redondo MJ, Hagopian WA, Oram R, Steck AK, Vehik K, Weedon M, Balasubramanyam A, Dabelea D. The clinical consequences of heterogeneity within and between different diabetes types. Diabetologia. 2020 Oct;63(10):2040-2048. doi: 10.1007/s00125-020-05211-7. Epub 2020 Sep 7. PMID: 32894314; PMCID: PMC8498993.
    See more on PubMed
  • Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, Greenbaum CJ, Herold KC, Krischer JP, Lernmark Å, Ratner RE, Rewers MJ, Schatz DA, Skyler JS, Sosenko JM, Ziegler AG. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015 Oct;38(10):1964-74. doi: 10.2337/dc15-1419. PMID: 26404926; PMCID: PMC5321245.
    See more on PubMed
  • Zajec A, Trebušak Podkrajšek K, Tesovnik T, Šket R, Čugalj Kern B, Jenko Bizjan B, Šmigoc Schweiger D, Battelino T, Kovač J. Pathogenesis of Type 1 Diabetes: Established Facts and New Insights. Genes (Basel). 2022 Apr 16;13(4):706. doi: 10.3390/genes13040706. PMID: 35456512; PMCID: PMC9032728.
    See more on PubMed
  • Marzinotto I, Pittman DL, Williams AJK, Long AE, Achenbach P, Schlosser M, Akolkar B, Winter WE, Lampasona V; participating laboratories. Islet Autoantibody Standardization Program: interlaboratory comparison of insulin autoantibody assay performance in 2018 and 2020 workshops. Diabetologia. 2023 May;66(5):897-912. doi: 10.1007/s00125-023-05877-9. Epub 2023 Feb 10. PMID: 36759347; PMCID: PMC10036445.
    See more on PubMed
  • Ziegler AG, Bonifacio E; BABYDIAB-BABYDIET Study Group. Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes. Diabetologia. 2012 Jul;55(7):1937-43. doi: 10.1007/s00125-012-2472-x. PMID: 22289814.
    See more on PubMed
  • Parikka V, Näntö-Salonen K, Saarinen M, Simell T, Ilonen J, Hyöty H, Veijola R, Knip M, Simell O. Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk. Diabetologia. 2012 Jul;55(7):1926-36. doi: 10.1007/s00125-012-2523-3. Epub 2012 Mar 23. PMID: 22441569.
    See more on PubMed
  • Krischer JP, Lynch KF, Schatz DA, Ilonen J, Lernmark Å, Hagopian WA, Rewers MJ, She JX, Simell OG, Toppari J, Ziegler AG, Akolkar B, Bonifacio E; TEDDY Study Group. The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study. Diabetologia. 2015 May;58(5):980-7. doi: 10.1007/s00125-015-3514-y. Epub 2015 Feb 10. PMID: 25660258; PMCID: PMC4393776.
    See more on PubMed
  • Ziegler AG, Hummel M, Schenker M, Bonifacio E. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes. 1999 Mar;48(3):460-8. doi: 10.2337/diabetes.48.3.460. PMID: 10078544.
    See more on PubMed
  • Hummel M, Bonifacio E, Schmid S, Walter M, Knopff A, Ziegler AG. Brief communication: early appearance of islet autoantibodies predicts childhood type 1 diabetes in offspring of diabetic parents. Ann Intern Med. 2004 Jun 1;140(11):882-6. doi: 10.7326/0003-4819-140-11-200406010-00009. PMID: 15172902.
    See more on PubMed
  • Yi L, Swensen AC, Qian WJ. Serum biomarkers for diagnosis and prediction of type 1 diabetes. Transl Res. 2018 Nov;201:13-25. doi: 10.1016/j.trsl.2018.07.009. Epub 2018 Aug 1. PMID: 30144424; PMCID: PMC6177288.
    See more on PubMed

Downloads

Safety information

Declaration of conformity

Find documents for the lot

Do you want to learn more about products? We're here for you.

Please fill in
all fields
marked *
Up